GlaxoSmithkline Pharmaceuticals recalls ranitidine hydrochloride tablets

26 Sep 2019 Evaluate

GlaxoSmithkline Pharmaceuticals has recalled ranitidine hydrochloride tablets produced in India using API sourced from Saraca Laboratories following detection of genotoxic nitrosamine NDMA by authorities.

The company has also decided to suspend release, distribution and supply of all dose forms of ranitidine hydrochloride products to all markets, including India, as a precautionary action pending the outcome of ongoing tests and investigations.

GlaxoSmithKline Pharmaceuticals (GSK Rx India) is one of the oldest pharmaceuticals company. The GSK India product portfolio includes prescription medicines and vaccines.

Glaxosmithkline Phar Share Price

2610.00 18.60 (0.72%)
11-Dec-2025 13:21 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1799.75
Dr. Reddys Lab 1274.70
Cipla 1509.75
Zydus Lifesciences 924.85
Lupin 2081.40
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×